Additional adherence support is important in these patients as the reason triple-class failure has occurred often relates to past poor adherence. Additionally, the pill burden is increased and careful discussion with the patient should take place. We recommend accessing newer agents through research trials, expanded access and named patient programmes (GPP). We suggest continuing/commencing NRTIs as this may contribute partial ARV activity to a regimen, despite drug resistance (2C). We recommend the use of 3TC or FTC to maintain a mutation at codon position

184 of the RT gene (1B). Lumacaftor ic50 We recommend against discontinuing or interrupting ART (1B). We recommend against adding a single, fully active ARV because of the risk of further resistance (1D). We recommend against the use of MVC to increase the CD4 cell count in the absence of CCR5 tropic virus (1C). This situation PF-01367338 price usually occurs following attempts in patients with triple-class failure to achieve virological suppression with the newer agents and often indicates adherence issues have not been addressed successfully or sequential addition of the newer agents has occurred

without incomplete viral suppression and selection of resistance to the new drug. There is evidence from cohort studies that continuing therapy, even in the presence of viraemia and the absence of CD4 T-cell count increases, reduces the risk of disease progression [62, 63] whereas interruption may lead to a rapid fall in CD4 cell count and a rise in VL [64, 65]. Other studies suggest continued immunological and clinical benefits if the HIV RNA level Protirelin is maintained <10 000–20 000 copies/mL [66]. Continuing or commencing NRTIs, even in the presence of known resistance may contribute partial ARV activity [54, 55]. Hence, if the CD4 cell count is well maintained (>200 cells/μL), it may be better to continue the failing regimen and not change treatment until investigational agents are available that can be

put together with drugs, which may have only partial activity at best, to increase the likelihood of constructing virologically suppressive and durable regimen options. In general, adding a single, fully active ARV to a failing regimen is not recommended because of the risk of rapid development of resistance. However, in patients with a high likelihood of clinical progression (e.g. CD4 cell count <100 cells/mL) and limited drug options, adding a single drug may reduce the risk of immediate clinical progression, because even transient decreases in HIV RNA and/or transient increases in CD4 cell counts have been associated with clinical benefits [67]. Potential benefits must be balanced with the ongoing risk of accumulating additional resistance mutations and patients should maintain that regimen for the shortest period possible [68, 69].